WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018
Nov 29, 2018, 08:22 ET
SHANGHAI and TOKYO, Nov. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has been selected as Forbes Asia's Best Under A Billion 2018.
Forbes Asia's Best Under A Billion 2018 list highlights 200 leading public companies in the Asia Pacific region with annual revenue under $1 billion. From a diverse group of 24,000 companies, qualified candidates are screened on sales growth and earnings growth in the past 12 months and over three years, and for the strongest five-year return on equity. After careful screening, a final list featuring 200 exceptional small and medium-sized companies from Asia-Pacific is compiled, all leaders in their respective industry.
WuXi Biologics' inclusion in Forbes Asia's Best Under A Billion list honors the tremendous recognition that the company receives, particularly for its excellent operational results since establishment. WuXi Biologics' revenue and adjusted net profit grew at a CAGR of nearly 70% and over 140% respectively in the past three years with all operational indicators recording strong growth. Since listing on HKEX in June 2017, the company has achieved excellent performance in capital market and gained traction from investors.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
SOURCE WuXi Biologics